Literature DB >> 18854268

Histologic assessment and prognostic factors of malignant pleural mesothelioma treated with extrapleural pneumonectomy.

Andrea V Arrossi1, E Lin, David Rice, Cesar A Moran.   

Abstract

We studied 56 cases of malignant pleural mesothelioma (MPM) treated with extrapleural pneumonectomy (EPP). The slides from the EPP specimens were reviewed, and tumors were classified with the guidance of the World Health Organization classification of pleural tumors. Agreement between the histologic type from the EPP review and the diagnostic procedure (DP) reports was evaluated. Histologic and clinical parameters were also correlated with clinical outcome. There was a significant disagreement (P = .0001) between the histologic type in the DP reports and the EPP specimen review. The histologic type from the DP was associated with disease-specific survival (DSS); however, the histologic type from the EPP specimen was not associated with survival. Postoperative treatment was associated with DSS and with recurrence-free survival. Our study confirms that in many cases, final histopathologic typing of MPM is influenced by complete surgical resection and that initial biopsy should be carefully weighed in the treatment stratification.

Entities:  

Mesh:

Year:  2008        PMID: 18854268     DOI: 10.1309/AJCPHV33LJTVDGJJ

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  7 in total

Review 1.  Review of malignant pleural mesothelioma survival after talc pleurodesis or surgery.

Authors:  Emanuela Taioli; Maaike van Gerwen; Meredith Mihalopoulos; Gil Moskowitz; Bian Liu; Raja Flores
Journal:  J Thorac Dis       Date:  2017-12       Impact factor: 2.895

2.  A nuclear grading system is a strong predictor of survival in epitheloid diffuse malignant pleural mesothelioma.

Authors:  Kyuichi Kadota; Kei Suzuki; Christos Colovos; Camelia S Sima; Valerie W Rusch; William D Travis; Prasad S Adusumilli
Journal:  Mod Pathol       Date:  2011-10-07       Impact factor: 7.842

3.  Novel immunotherapy clinical trials in malignant pleural mesothelioma.

Authors:  Zachary E Tano; Navin K Chintala; Xiaoyu Li; Prasad S Adusumilli
Journal:  Ann Transl Med       Date:  2017-06

4.  Diagnostic value of biopsy sampling in predicting histology in patients with diffuse malignant pleural mesothelioma.

Authors:  Lucian R Chirieac; Yin P Hung; Wai Chin Foo; Matthias D Hofer; Paul A VanderLaan; William G Richards; David J Sugarbaker; Raphael Bueno
Journal:  Cancer       Date:  2019-08-07       Impact factor: 6.860

5.  Reproducibility of histological subtyping of malignant pleural mesothelioma.

Authors:  Luka Brčić; Marko Jakopović; Iva Brčić; Vlasta Klarić; Milan Milošević; Ana Sepac; Miroslav Samaržija; Sven Seiwerth
Journal:  Virchows Arch       Date:  2014-10-10       Impact factor: 4.064

6.  Global gene expression profiling of human pleural mesotheliomas: identification of matrix metalloproteinase 14 (MMP-14) as potential tumour target.

Authors:  Stefania Crispi; Raffaele A Calogero; Mario Santini; Pasquale Mellone; Bruno Vincenzi; Gennaro Citro; Giovanni Vicidomini; Silvia Fasano; Rosaria Meccariello; Gilda Cobellis; Simona Menegozzo; Riccardo Pierantoni; Francesco Facciolo; Alfonso Baldi; Massimo Menegozzo
Journal:  PLoS One       Date:  2009-09-15       Impact factor: 3.240

7.  Microcystic variant malignant mesothelioma presenting as a localized paraspinal mass.

Authors:  Hyang Mi Ko; Zaid Saeed Kamil; William R Geddie
Journal:  Cytojournal       Date:  2014-06-12       Impact factor: 2.091

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.